{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:25:16Z","timestamp":1788269116597,"version":"build-2803163510"},"reference-count":28,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1136\/bjophthalmol-2016-309887","type":"journal-article","created":{"date-parts":[[2017,3,19]],"date-time":"2017-03-19T00:20:11Z","timestamp":1489882811000},"page":"1471-1474","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Predictive factors for the placebo effect in clinical trials for dry eye: a pooled analysis of three clinical trials"],"prefix":"10.1136","volume":"101","clinical-trial-number":[{"clinical-trial-number":"nct01189032","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Takahiro","family":"Imanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,3,18]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2016-309887-1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"key-10.1136\/bjophthalmol-2016-309887-2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1542-0124(12)70085-X","article-title":"Management and therapy of dry eye disease: report of the management and therapy subcommittee of the international dry eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"key-10.1136\/bjophthalmol-2016-309887-3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1542-0124(12)70084-8","article-title":"Design and conduct of clinical trials: report of the clinical trials subcommittee of the international dry eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"key-10.1136\/bjophthalmol-2016-309887-4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","article-title":"Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial","volume":"131","author":"Amparo","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309887-5","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","article-title":"Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial","volume":"119","author":"Matsumoto","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309887-6","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","article-title":"Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study","volume":"119","author":"Kinoshita","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309887-7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","article-title":"Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye","volume":"23","author":"Tauber","year":"2004","journal-title":"Cornea"},{"key":"key-10.1136\/bjophthalmol-2016-309887-8","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309887-9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309887-10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309887-11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/sim.4780020401","article-title":"How much of the placebo \u2019effect' is really statistical regression?","volume":"2","author":"McDonald","year":"1983","journal-title":"Stat Med"},{"key":"key-10.1136\/bjophthalmol-2016-309887-12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.sleep.2011.03.009","article-title":"Night-to-night variability of sleep latency significantly predicts the magnitude of subsequent change in sleep latency during placebo administration","volume":"12","author":"Ogawa","year":"2011","journal-title":"Sleep Med"},{"key":"key-10.1136\/bjophthalmol-2016-309887-13","doi-asserted-by":"crossref","first-page":"e0156706","DOI":"10.1371\/journal.pone.0156706","article-title":"Factors influencing the placebo effect in patients with primary open-angle glaucoma or ocular hypertension: an analysis of two randomized clinical trials","volume":"11","author":"Kawamura","year":"2016","journal-title":"PLoS One"},{"key":"key-10.1136\/bjophthalmol-2016-309887-14","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1001\/jama.1955.02960340022006","article-title":"The powerful placebo","volume":"159","author":"Beecher","year":"1955","journal-title":"J Am Med Assoc"},{"key":"key-10.1136\/bjophthalmol-2016-309887-15","doi-asserted-by":"crossref","first-page":"e62599","DOI":"10.1371\/journal.pone.0062599","article-title":"Are treatments more effective than placebos? A systematic review and meta-analysis","volume":"8","author":"Howick","year":"2013","journal-title":"PLoS One"},{"key":"key-10.1136\/bjophthalmol-2016-309887-16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0895-4356(01)00496-6","article-title":"What are the main methodological problems in the estimation of placebo effects?","volume":"55","author":"Hr\u00f3bjartsson","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"key-10.1136\/bjophthalmol-2016-309887-17","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.ophtha.2011.05.029","article-title":"Prevalence and risk factors of dry eye disease in Japan: Koumi study","volume":"118","author":"Uchino","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309887-18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","article-title":"Prevalence of dry eye syndrome among US women","volume":"136","author":"Schaumberg","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309887-19","first-page":"363","article-title":"[Age-related changes in the mucocutaneous junction and the conjunctivochalasis in the lower lid margins]","volume":"107","author":"Hirotani","year":"2003","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"key-10.1136\/bjophthalmol-2016-309887-20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ajo.2008.07.010","article-title":"Changes of conjunctivochalasis with age in a hospital-based study","volume":"147","author":"Mimura","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309887-21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/ICO.0b013e31802e1e24","article-title":"Delayed tear clearance in patients with conjunctivochalasis is associated with punctal occlusion","volume":"26","author":"Erdogan-Poyraz","year":"2007","journal-title":"Cornea"},{"key":"key-10.1136\/bjophthalmol-2016-309887-22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ICO.0b013e3181861d0c","article-title":"Elevated tear interleukin-6 and interleukin-8 levels in patients with conjunctivochalasis","volume":"28","author":"Erdogan-Poyraz","year":"2009","journal-title":"Cornea"},{"key":"key-10.1136\/bjophthalmol-2016-309887-23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4088\/JCP.14r09297","article-title":"The nature of placebo response in clinical studies of major depressive disorder","volume":"76","author":"Papakostas","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"key-10.1136\/bjophthalmol-2016-309887-24","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4088\/JCP.10m05979pur","article-title":"Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD","volume":"72","author":"Waxmonsky","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"key-10.1136\/bjophthalmol-2016-309887-25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000365248","article-title":"Age and sex as moderators of the placebo response \u2013 an evaluation of systematic reviews and meta-analyses across medicine","volume":"61","author":"Weimer","year":"2015","journal-title":"Gerontology"},{"key":"key-10.1136\/bjophthalmol-2016-309887-26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"key":"key-10.1136\/bjophthalmol-2016-309887-27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309887-28","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamaophthalmol.2013.4503","article-title":"Development and validation of the Dry Eye-Related Quality-of-Life score questionnaire","volume":"131","author":"Sakane","year":"2013","journal-title":"JAMA Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2016-309887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:54:29Z","timestamp":1601110469000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2016-309887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,18]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,10,25]]},"published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1136\/bjophthalmol-2016-309887"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309887","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,18]]}}}